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Abstract: Retinal degenerations leading to the loss of photoreceptor (PR) cells are a major 
cause of vision impairment and untreatable blindness. There are few clinical treatments and 
none can reverse the loss of vision. With the rapid advances in stem cell biology and 
techniques in cell transplantation, PR replacement by transplantation represents a broad 
treatment strategy applicable to many types of degeneration. The number of donor cells that 
integrate into the recipient retina determines transplantation success, yet the degenerating 
retinae presents a number of barriers that can impede effective integration. Here, we briefly 
review recent advances in the field of PR transplantation. We then describe how different 
aspects of gliosis may impact on cell integration efficiency.  
 
XX1. Introduction: 
Despite very different aetiologies and pathogenesis, retinal neurodegenerative diseases like 
age-related macular degeneration, retinitis pigmentosa (RP), glaucoma and diabetic 
retinopathy culminate in the loss of light-sensing PR cells and the subsequent loss of vision. 
Currently, there are few effective therapeutic approaches to treat PR loss, and none of them 
can reverse the loss of vision. Innovative medical therapies such as electronic retinal implants 
(Stingl and Zrenner 2013), or gene and cell therapy (Cuenca et al. 2014) are attractive 
approaches for the treatment of retinal disease. Gene therapy for the treatment of inherited 
retinal disorders has yielded very exciting and promising results (Smith et al. 2012), however 
this therapeutic strategy can only be applied in the early stages of retinal degeneration as it 
relies on the presence of the endogenous PR cells, offering limited help for advanced disease. 
Cell replacement therapy is of particular interest in this particular circumstance as it offers a 
direct replacement of the lost tissue and can potentially restore visual function. Over the past 
decade, we have seen a considerable progress in using this approach to repair the 
degenerating retina (Cuenca et al. 2014). However, it has been shown that although it is 
possible to treat some forms of end stage (Kwan et al. 1999; Singh et al. 2013), the precise 
nature and characteristics of the degeneration arising from a given disease-causing defect is 
important in determining transplantation outcome. As degeneration progresses the retinal 
microenvironment undergoes a number of significant changes that are potentially hostile to 
therapeutic interventions. A number of studies have indicated that a major determinant of 
successful retinal transplantation is the extent of reactive gliosis within the recipient retina, 
which acts as both a physical and chemical barrier to migrating cells (Pearson et al. 2014). 
 
XX2. Advances in the field of PR transplantation: 
In recent years, one of the most extensively studied therapeutic strategies has been the 
transplantation of dissociated PRs and their precursor cells. MacLaren et al. demonstrated 
that integration and appropriate differentiation of donor PR cells is achievable if the 
transplanted cells are at an appropriate developmental stage at the time of transplantation 
(MacLaren et al. 2006). The use of a genetic marker, Nrl, a transcription factor first expressed 
in immature rods shortly after terminal mitosis (Akimoto et al. 2006), demonstrated that post-
mitotic rod precursor cells taken from postnatal retinae were optimal for transplant and led to 
better integration than donor cells from earlier or later stages in development. These 
transplanted PR precursors were able to migrate from the site of transplantation, the 
subretinal space, into the recipient outer nuclear layer (ONL), where they settled in an 
appropriate place. The new PRs continue to mature and form inner and outer segments and 
synaptic connections with the remaining neurons within the retina (Warre-Cornish et al. 
2013). Moreover, these new PRs are light sensitive and can transmit visual information to the 
brain, leading to restoration of visual function in a murine model of stationary night blindness 
(Pearson et al. 2012). Recent advances in stem cell technology have demonstrated the 
potential to generate renewable sources of donor cells from embryonic (ES) and induced 
pluripotent stem cells. Gonzalez-Cordero et al. have shown that ES-derived rod precursors 
can migrate and integrate into the recipient retina in a manner very similar to precursors 
derived from the developing retina (Eiraku et al. 2011; Gonzalez-Cordero et al. 2013). 
Much of the research into PR transplantation has been performed in wild-type or isolated 
models of RP. This raises the fundamental question as whether PR transplantation is equally 
able to treat a wide spectrum of inherited retinopathies. It is well known that during disease 
progression the retina undergoes structural remodeling, including changes in neuronal 
connections, gliosis and changes in outer limiting membrane integrity (OLM). These changes 
may then have a positive or negative influence on the outcome of PR precursor cell 
transplantation. Barber et al. performed the first comprehensive study of rod PR 
transplantation in murine models of slow, moderate and fast PR degeneration. Importantly, 
they found that PR transplantation was feasible in all examined animals; however disease 
type had a significant impact on both the number of integrated cells and their morphology. 
This study identified two key determinants of transplant success; the extent of glial scarring 
and the integrity of OLM. Both factors can impede the migration of donor cells from the 
subretinal space and their successful integration within the recipient retina. Below, we focus 
on gliosis and its impact on cell transplantation. 
 
XX3. Gliosis a potential barrier to photoreceptor transplantation: 
Gliosis is the term given to the process in which the glial cells become activated. When these 
cells are activated, they upregulate the glial intermediate filament (IF) proteins vimentin and 
glial fibrillary acidic protein (GFAP), their apical terminal processes may undergo 
hypertrophy and a concomitant increase in the deposition of inhibitory extracellular matrix 
(ECM) molecules, such as chondroitin sulphate proteoglycans (CSPGs) can be observed. 
These changes represent physical and biochemical barriers, respectively, which may prevent 
transplanted PRs from reaching the recipient retina.  
 
XX3.1. Glial cell hypertrophy may act as a physical barrier: 
In the retina, Müller glia (MG) span the entire thickness of the vertebrate retina and represent 
the major type of glial cells. They are responsible for the structural stabilization of the retina, 
support the functioning and metabolism of retinal neurons and are active players in normal 
retinal function as well as in virtually all types of retinal degeneration where they undergo 
reactive gliosis (Bringmann et al. 2006).  Gliosis in the retina can be induced by mechanical 
insult (Lewis et al. 2010), retinal degeneration (Zhang et al. 2003), inflammation (Dinet et al. 
2012) and/or ageing (Kim et al. 2004). It includes morphological, biochemical and 
physiological changes, which can vary with the type and severity of the insult. One of the 
readily detectable responses to retinal diseases and injuries, which is often used as a universal 
early cellular marker for retinal injury, is the upregulation of the IF protein, GFAP (Dahl 
1979). In a healthy retina expression of GFAP+ve IF is largely restricted to astrocytes with 
only a few GFAP+ve Müller glial processes detected in the inner retina. In the diseased retina, 
GFAP is increased in both activated cell types. The level and localisation of GFAP IF 
expression in the MG processes is disease specific (Hippert et al., unpublished data). The 
increased expression of IFs is thought to help stabilize the newly formed terminal processes 
of MG and provide resistance to mechanical stress (Verardo et al. 2008).  At first, gliosis 
seems to represent a cellular attempt to protect the tissue from further damage to promote 
repair and to limit neuronal remodeling. However, MG activation can also be exacerbated 
and lead to the hypertrophy of the MG end-feet processes, which fill in the gaps where PRs 
die (Bringmann et al. 2006). This contributes to the formation of a glial scar in the subretinal 
space which may impair neurite outgrowth and act as a barrier to regenerating and/or 
transplanted cells. Supporting this view are the findings that transgenic animals lacking both 
GFAP and vimentin in MG shown a more permissive environment for the grafted cells as 
shown by better integration and differentiation of transplanted cells as well as a higher neurite 
outgrowth than in wild-type recipients (Kinouchi et al. 2003). In line with this, Barber et al. 
(2013) reported that transplantation outcome of rod precursor cells in different models of 
inherited blindness is broadly inversely correlated with the extent of GFAP expression.  
 
XX3.2. The extracellular matrix changes may act as a chemical barrier: 
The retinal environment, like elsewhere in the CNS, is enriched in CSPGs. These include a 
variety of core proteins each carrying chondroitin sulphate glycosaminoglycans (GAG) 
chains. CSPGs bind many different ECM proteins and growth factors making them important 
players in a variety of regulatory processes including cell adhesion, migration and 
differentiation (Ichijo 2004). In the CNS, CSPGs are upregulated after injury and participate 
in the inhibition of axon regeneration mainly through their GAG side chains. Application of 
the bacterial enzyme chondroitinase ABC (ChABC), which degrades GAG chains into 
disaccharides, promotes functional recovery in the injured CNS (Bradbury et al. 2002). In 
retinal degeneration our understanding of the role of CSPGs is surprisingly limited. In the 
healthy retina, CSPGs are found in several regions including the optic nerve, inner and outer 
plexiform layer, the interphotoreceptor matrix and in the ganglion cell layer (Inatani and 
Tanihara 2002). When using a broad spectrum CSPG antibody in murine models of RP, we 
have observed marked variations in the level of expression of CSPGs (Hippert et al., 
unpublished data). Numerous studies with both stem cell and PR precursor transplants 
demonstrated that treatment with ChABC prior the transplantation increased the number and 
survival of integrated donor cells (Singhal et al. 2008; Ma et al. 2011; Barber et al. 2013). An 
improvement of viral vector diffusion and transduction has also been described when 
applying this enzyme in conjunction with lentiviral vector to the sub-retinal space (Grüter et 
al. 2005).  
 
XX4. Conclusion, Importance of characterizing retinal environment changes:  
Dependent on the ocular disease type, different changes occur in the retina which lead to 
altered retinal microenvironments. A better understanding and characterization of these 
changes is essential for the development of new therapeutic approaches. To our knowledge 
no drugs have been able to show an efficient removal of IF proteins to overcome the glial 
scar barrier. We are using RNA interference to modulate the expression of GFAP in 
conjunction with PR precursor transplantation, to establish the precise role of GFAP in 
impeding donor cell integration (unpublished data). Currently, local treatment with ChABC is 
the major strategy to override the inhibitory effect of CSPGs on cell-based therapies. 
However, ChABC presents some disadvantages in using it as a therapeutic treatment in 
patients, including the potential for inflammatory reaction due to its bacterial origin (Lee et 
al. 2010). A more detailed characterization of the major changes in ECM composition may 
enable the identification of specific CSPGs that undergo potentially disease-specific changes. 
This may enable targeted breakdown of specific CSPGs and enhance cell transplantation 
efficiency. Our focus here has been gliosis as a barrier to cell transplantation, however other 
barriers exist. Different studies reported that the OLM may also act as a physical barrier to 
cell transplantation (West et al. 2008; Pearson et al. 2010). Finally, combining cell 
transplantation with the manipulation of two or more barriers will be another interesting 
approach to investigate. We recently combined OLM disruption and CSPG degradation with 
encouraging results (Barber et al. 2013), while others have combined ChABC with growth 
factors (IGF-1)(Ma et al. 2011).  
 
In summary, significant progress has been made in the field of PR transplantation therapy but 
achieving high numbers of new integrated PRs in the diseased retina remains a major 
challenge. A better understanding of the microenvironmental changes in the degenerating 
retina should help to overcome this. 
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